Study guide

6.4 Bioavailability, Bioequivalence, Biosimilars, and Pharmacogenomics

NABP FPGEE Foreign Pharmacy Graduate Equivalency Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the FPGEE 1.2 How to Use This Study Guide

2 Chapter 2: Foundational Biomedical Sciences I

2.1 Anatomy 2.2 Physiology 2.3 Biochemistry

3 Chapter 3: Foundational Biomedical Sciences II

3.1 Medical Microbiology 3.2 Immunology 3.3 Pathophysiological Bases of Diseases

4 Chapter 4: Pharmaceutical Calculations, Compounding, and Medicinal Chemistry

4.1 Pharmaceutical Calculations 4.2 Extemporaneous Compounding 4.3 Physicochemical Properties, ADME, and Drug Metabolism Pathways 4.4 Structure-Activity Relationships and Drug-Receptor Interactions

5 Chapter 5: Pharmacology and Toxicology

5.1 Pharmacodynamics and Dose-Response 5.2 Mechanisms of Action of Drugs and Biologics 5.3 Adverse Effects, Side Effects, and Drug Interactions 5.4 Toxicology and Antidotes

6 Chapter 6: Pharmaceutics, Biopharmaceutics, and Pharmacokinetics

6.1 Dosage Forms, Drug Delivery, and Dissolution 6.2 Stability, Shelf-Life, and Manufacturing 6.3 ADME Rates, Half-Lives, and Compartment Models 6.4 Bioavailability, Bioequivalence, Biosimilars, and Pharmacogenomics

7 Chapter 7: Pharmacy Law, Ethics, and Health Care Systems

7.1 Pharmacy Law and Regulations 7.2 Ethics and Regulatory/Oversight Organizations 7.3 US Health Care Systems 7.4 Pharmacoeconomics

8 Chapter 8: Public Health, Practice Management, and Biostatistics

8.1 Pharmacoepidemiology, Population-Based Care, and Public Health 8.2 Practice Management 8.3 Continuous Quality Improvement, Risk Management, and Inventory Control 8.4 Biostatistics and Research Methods

9 Chapter 9: Professional Communication and Behavioral Aspects

9.1 Professional Communication 9.2 Social and Behavioral Aspects of Practice

10 Chapter 10: Clinical Sciences I — Pathophysiology and Patient Assessment

10.1 Clinical Pathophysiology: Cardiovascular and Endocrine 10.2 Clinical Pathophysiology: Respiratory, GI, Renal, and Other Systems 10.3 Patient Data Collection 10.4 Patient Data Assessment 10.5 Patient-Care Decision Making, Therapy Recommendations, and Education

11 Chapter 11: Clinical Sciences II — Patient Safety, Prevention, and Personalized Care

11.1 Patient Safety: Drug Interactions and Toxicity 11.2 Drug-Induced Disease and Drug Use Disorders 11.3 Disease Prevention 11.4 Personalized Medicine

12 Chapter 12: Clinical Sciences III — Evidence-Based Practice

12.1 Practice Guidelines and Drug Information 12.2 Clinical Trial Evaluation and Information Source Reliability

13 Chapter 13: Clinical Sciences IV — Self-Care and Natural Products

13.1 Self-Care and Natural Products

6.4 Bioavailability, Bioequivalence, Biosimilars, and Pharmacogenomics

Key Takeaways Explain This Topic AI

Absolute bioavailability compares oral AUC to IV AUC; relative bioavailability compares one non-IV product to another reference non-IV product.

FDA bioequivalence requires the 90% confidence interval of the test/reference ratio for AUC and Cmax to fall within 80-125%, a symmetric region in log scale.

Biosimilars are highly similar but not identical to reference biologics; they require separate 351(k) approval, may retain immunogenicity, and are not automatically substituted like small-molecule generics.

Pharmacogenomic biomarkers (CYP2C19, CYP2D6, HLA-B*5701, TPMT, CYP2C9/VKORC1) alter metabolism, efficacy, or toxicity of many commonly prescribed drugs.

Warfarin dosing integrates CYP2C9 metabolism and VKORC1 sensitivity to predict maintenance dose; tumor genotyping (HER2, EGFR, KRAS, BRAF) guides targeted oncology therapy.

Last updated: September 2026

Bioavailability: Definitions and Metrics

Bioavailability is the fraction of administered dose reaching systemic circulation unchanged, plus the rate at which it appears. Three parameters characterize a plasma concentration-time curve:

Cmax — peak plasma concentration; relates to peak pharmacologic effect and acute toxicity.

Tmax — time to Cmax; reflects absorption rate.

AUC (area under the curve) — total exposure; proportional to absorbed dose when clearance is constant.

Absolute bioavailability compares an extravascular route (typically oral) to IV: F = (AUC_po · Dose_iv) / (AUC_iv · Dose_po). IV F is by definition 1.0. Relative bioavailability compares two non-IV formulations (e.g., a generic tablet to a brand tablet).

AUC is computed numerically with the linear trapezoidal rule between sampled time points, then extrapolated to infinity by adding C_last / k, where k is the terminal elimination rate constant. Non-compartmental analysis is the regulatory standard because it makes no structural model assumptions.

Bioequivalence and FDA Standards

Two products are bioequivalent if their rate and extent of absorption are so similar that they are expected to produce the same clinical effect and safety profile. FDA requires a two-way crossover study in healthy volunteers under fasting or fed conditions, with single and multiple doses as appropriate.

The decision rule: the 90% confidence interval of the geometric mean test/reference ratio for both AUC and Cmax must lie within 0.80 to 1.25 (in natural log scale this is a symmetric interval of ±ln(1.25)). The 80-125% bounds are not the same as a 20% allowable difference — they are a symmetric region on the log scale that the FDA adopted to control Type I and Type II error for both directions of inequality. Tmax differences are assessed only descriptively, except for products where onset matters (e.g., analgesics).

A drug product meeting bioequivalence standards can be substituted at the pharmacy under FDA's AB-rating (Orange Book). Therapeutic equivalence also requires the same active ingredient, dosage form, strength, route, and labeling.

Biosimilars vs Generics

A generic small-molecule drug is chemically identical to its reference listed drug and can be substituted without prescriber notification after FDA AB-rating.

A biosimilar is a biologic product that is highly similar to the reference biologic, with no clinically meaningful differences in safety, purity, or potency. Because biologics are produced in living cells, post-translational modifications (glycosylation, deamidation, aggregation) cannot be perfectly replicated.

Biosimilars are approved through the 351(k) pathway of the Biologics Price Competition and Innovation Act (BPCIA) . They require analytical, animal, and clinical studies (often a pharmacokinetic/pharmacodynamic equivalence study in a sensitive indication). Extrapolation of indications is permitted if the mechanism of action and safety are expected to be the same across the reference product's approved uses.

Interchangeability is a higher FDA standard: an interchangeable biosimilar may be substituted for the reference product by a pharmacist without prescriber intervention, subject to state law. Immunogenicity remains a residual risk; anti-drug antibodies can reduce efficacy or cause hypersensitivity, so post-marketing surveillance is mandatory.

Pharmacogenomics: Population-Based Genetic Variation

Pharmacogenomics (PGx) studies how genome variation affects drug response. The FDA labels many drugs with PGx information; the Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes peer-reviewed dosing guidelines.

Biomarker Drug(s) Phenotype / Risk Clinical Action

CYP2C19 Clopidogrel Loss-of-function alleles → poor activation Avoid clopidogrel in poor metabolizers; use prasugrel or ticagrelor after PCI

CYP2D6 Codeine, tramadol Ultra-rapid metabolizers → excessive morphine formation; poor metabolizers → inadequate analgesia Avoid codeine/tramadol in ultra-rapid metabolizers and breastfeeding; choose alternative analgesic

CYP2D6 Tamoxifen Poor metabolizers → lower endoxifen, higher recurrence Consider aromatase inhibitor in postmenopausal poor metabolizers

HLA-B*5701 Abacavir Carriers → hypersensitivity syndrome Test before starting; do not prescribe abacavir to carriers

HLA-B*1502 Carbamazepine, oxcarbazepine Carriers (mainly Han Chinese, Thai) → Stevens-Johnson syndrome / TEN Test at-risk ancestry before therapy; avoid if positive

TPMT / NUDT15 Azathioprine, 6-MP Low activity → severe myelosuppression Reduce starting dose or choose alternative; NUDT15 captures East-Asian risk TPMT misses

CYP2C9 + VKORC1 Warfarin Variant combinations → lower maintenance dose Use dosing algorithm; reduce initial dose for combined low-function genotypes

DPD (DPYD) 5-Fluorouracil, capecitabine Deficiency → severe mucositis, neutropenia Reduce dose or avoid in deficient patients

G6PD Rasburicase, primaquine, dapsone, sulfonamides Deficiency → hemolytic anemia Screen at-risk populations before administration

Warfarin Dosing and Genotype

CYP2C9 affects S-warfarin clearance; VKORC1 affects warfarin sensitivity. The star in an allele name is part of its identifier: CYP2C9 *1/*1 differs from genotypes containing reduced-function alleles such as *2 or *3 .

When genotype results are available, CPIC recommends an appropriate validated pharmacogenetic dosing algorithm that combines genetic and clinical information. A universal percentage reduction or one fixed dose cannot be inferred from an allele name alone. Other variants and ancestry can affect which algorithm or tests are appropriate. INR monitoring and clinical response remain necessary throughout therapy.

Tumor Genotyping for Targeted Therapy

Somatic tumor mutations drive therapy selection in oncology:

HER2 amplification — trastuzumab, pertuzumab, ado-trastuzumab emtansine in breast and gastric cancer; test by IHC/FISH before therapy.

EGFR mutations (exon 19 deletion, L858R) — erlotinib, gefitinib, osimertinib in non-small cell lung cancer; T790M predicts first-generation TKI resistance and osimertinib sensitivity.

KRAS G12C — sotorasib, adagrasib in NSCLC; historically "undruggable."

BRAF V600E — vemurafenib, dabrafenib (with trametinib) in melanoma, NSCLC, anaplastic thyroid; combined with MEK inhibition to delay resistance.

BCR-ABL — imatinib, dasatinib, nilotinib in CML.

PD-L1 expression (TPS) — pembrolizumab first-line NSCLC if TPS ≥ 50% without actionable driver mutation.

Preemptive Genotyping in Practice

Preemptive genotyping sequences a panel of relevant genes before prescribing, embedding results in the EHR so that alerts fire when a relevant drug is ordered. Preemptive panels cover CYP2D6, CYP2C19, CYP2C9, CYP3A5, TPMT, NUDT15, SLCO1B1 (statin myopathy risk), HLA-B 5701, HLA-B 1502, DPYD, and G6PD. CPIC Level A and B guidelines prioritize drug-gene pairs with strong evidence and actionable alternatives. FDA drug labeling uses terms "Test before dosing," "Recommended use," or "Informational" to communicate PGx strength.

Loading diagram... FDA Bioequivalence Decision Rule — 90% CI of Test/Reference Ratio Within 0.80-1.25